Multiple Sclerosis News Today (June 27) discusses a report issued by Spherix Global Insights, entitled "After Ocrevus approval, new MS therapies may become available, report suggests":
Only registered and activated users can see links., Click Here To Register...
I'm not familiar with Spherix Global Insights but found out that it has been around for only 3 years. It seems to be an information provider for anyone interested in investing in pharmaceuticals but I'm not sure.
One of the drugs discussed, MD-1003, is also known as high-dose biotin.
Only registered and activated users can see links., Click Here To Register...
I'm not familiar with Spherix Global Insights but found out that it has been around for only 3 years. It seems to be an information provider for anyone interested in investing in pharmaceuticals but I'm not sure.
One of the drugs discussed, MD-1003, is also known as high-dose biotin.

Comment